Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCRX Biocryst Pharmaceuticals

Not Yet Opened 01-12 16:00:00 EST

7.09

-0.31

-4.19%

盘后7.13

+0.04+0.56%

19:42 EST

High7.33	Low6.99	Vol7.81M
Open7.30	D1 Closing7.40	Amplitude4.59%
Mkt Cap1.49B	Tradable Cap1.47B	Total Shares210.74M
T/O55.52M	T/O Rate3.76%	Tradable Shares207.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"Biocryst Pharmaceuticals","latestPrice":7.09,"timestamp":1768251600000,"preClose":7.4,"halted":0,"volume":7805727,"hourTrading":{"tag":"盘后","latestPrice":7.13,"preClose":7.09,"latestTime":"19:42 EST","volume":65005,"amount":461144.4728,"timestamp":1768264979634},"delay":0,"floatShares":207688912,"shares":210739061,"eps":-0.045319,"marketStatus":"Not Yet Opened","change":-0.31,"latestTime":"01-12 16:00:00 EST","open":7.3,"high":7.33,"low":6.99,"amount":55524938.406993,"amplitude":0.045946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.045319,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":7.4,"preHourTrading":{"tag":"盘前","latestPrice":7.34,"preClose":7.4,"latestTime":"09:29 EST","volume":20748,"amount":156361.762284,"timestamp":1768228199999},"postHourTrading":{"tag":"盘后","latestPrice":7.13,"preClose":7.09,"latestTime":"19:42 EST","volume":65005,"amount":461144.4728,"timestamp":1768264979634},"volumeRatio":1.693594,"impliedVol":0.39,"impliedVolPercentile":0.316},"requestUrl":"/m/hq/s/BCRX","defaultTab":"news","newsList":[{"id":"2602512321","title":"GUIDANCE: (BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512321?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:18","pubTimestamp":1768220314,"startTime":"0","endTime":"0","summary":"GUIDANCE: (BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX"],"gpt_icon":0},{"id":"2602951464","title":"BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602951464","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602951464?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219253,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO  of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue, full-year 2025 net revenue was $563 million, up 43 percent on a comparable basis. For the fourth quarter of 2025, ORLADEYO net revenue reached $151 million, a 22 percent year-over-year rise, or 36 percent when excluding European revenue. Looking ahead, BioCryst expects ORLADEYO net revenue to be between $625 million and $645 million in 2026. The company also anticipates continued non-GAAP profitability in 2026, even after the expected close of its proposed acquisition of Astria Therapeutics in the first quarter of 2026. Non-GAAP operating expenses, including the Astria acquisition, are projected to be between $450 million and $470 million for 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL551Ybs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210149790.SGD","LU2210150020.SGD","BCRX","NDAQ","BK4139","BK4585","LU2095319765.USD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","BK4112","SG9999014039.USD","ATXS","IE00B64PRP62.GBP","BK4547","LU0314104364.USD"],"gpt_icon":0},{"id":"2602514639","title":"BioCryst Pharmaceuticals Inc: Expects Continued Non-Gaap Profitability in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514639?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA2S1L6B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2602514544","title":"BioCryst Announces Preliminary Full Year 2025 Orladeyo® (Berotralstat) Net Revenue of $601 Million (+37 Percent Y-O-Y), Beating Prior Guidance Range","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514544?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA2S1L6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4213","BK4139","BCRX","BK4547","BK4588","BK4585","RRC"],"gpt_icon":0},{"id":"2602514189","title":"BioCryst Pharmaceuticals Inc Outlook FY 2026 Total Revenue $635 Mln to $660 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514189?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA2S1L6B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2602307250","title":"BioCryst Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Commercial Officer Ronald Dullinger","url":"https://stock-news.laohu8.com/highlight/detail?id=2602307250","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602307250?lang=en_us&edition=fundamental","pubTime":"2026-01-10 08:20","pubTimestamp":1768004423,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Ronald Dullinger, Chief Commercial Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL5w2pgs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCryst Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Commercial Officer Ronald Dullinger","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2602307155","title":"Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2602307155","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602307155?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:18","pubTimestamp":1767997119,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent share price moves, with the stock last closing at US$7.62. For a rare disease focused biotech, that puts current performance and ongoing drug development firmly in focus.\nSee our latest analysis for BioCryst Pharmaceuticals.\nRecent trading has been a bit choppy, with a 1 day share price return of a 3.79% decline and a 7 day share price return of a 2.31% decline, while the 90 day share price return of 5.54% contrasts...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2602237811","title":"BioCryst Pharmaceuticals Inc - Increases Orladeyo Price to $48,487.92 per 28-Day Pack - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602237811","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602237811?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:02","pubTimestamp":1767960164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA0Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2601336509","title":"RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336509","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601336509?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:48","pubTimestamp":1767872892,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) has an average rating of buy and mean price target of $20.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"2595579400","title":"BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2595579400","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595579400?lang=en_us&edition=fundamental","pubTime":"2025-12-30 20:22","pubTimestamp":1767097366,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals  faces multiple near-term catalysts and a strong commercial business that make 2026 a critical year for the company, Wedbush said in a note Tuesday.Wedbush analysts said that BioCryst's planned acquisition of Astria Therapeutics is \"an important catalyst to expand the pipeline with navenibart.\" Preliminary data shows robust attack rate reduction with extended dosing, and phase 3 data remains on track for early 2027, the analysts said.While phase 1 data for BCX17725 in Netherton syndrome is not priced in the stock, it could \"be a nice call option,\" Wedbush added, citing recent data showing 90%-92% hereditary angioedema  attack rate reductions at three and six months doses.Wedbush said BioCryst shares trade at a discount compared with peers as investors are concerned about Orladeyo revenue longevity, however, Wedbush believes the Astria deal provides an important offset.Wedbush sees navenibart as a key revenue growth driver and expects BioCryst's total revenue to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4198","BK4139","IE00B19Z6F94.USD","IE00B64QTZ34.USD","LU0205193047.USD","LU0205194284.USD","IE00BLDYK493.USD","LU1169589451.USD","LU1169590202.USD","LU0012050646.USD","LU0106261612.USD","IE0034390439.USD","HAE","BK4547","BCRX"],"gpt_icon":0},{"id":"2593202445","title":"Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2593202445","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593202445?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:16","pubTimestamp":1766528207,"startTime":"0","endTime":"0","summary":"Astria Therapeutics, Inc. is set to merge with BioCryst Pharmaceuticals, Inc., following an agreement in which Astria will become a wholly owned subsidiary of BioCryst. As part of the process, a registration statement and definitive proxy statement have been filed. Recent updates include the disclosure of two lawsuits filed in New York against Astria and its board members, alleging negligence and misrepresentation related to the registration statement. Astria has stated it believes the claims are without merit and intends to vigorously defend against the litigation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL20vQMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX","ATXS"],"gpt_icon":0},{"id":"2593443338","title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443338","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593443338?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:12","pubTimestamp":1766524338,"startTime":"0","endTime":"0","summary":"Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLb4jLPl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2592937480","title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937480","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937480?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:13","pubTimestamp":1765919621,"startTime":"0","endTime":"0","summary":"Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL9BgrRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4139","BK4547"],"gpt_icon":0},{"id":"2591323628","title":"BioCryst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591323628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591323628?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:58","pubTimestamp":1765814280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 10:58 ET (15:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"2591644162","title":"BioCryst Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $32 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644162?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:04","pubTimestamp":1765807491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nAZN4RF5A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2590250290","title":"BioCryst Pharmaceuticals Shares Reverse Premarket Course, Last Down 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590250290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590250290?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:39","pubTimestamp":1765550341,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI11T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2590047895","title":"Sector Update: Health Care Stocks Edge Higher Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2590047895","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590047895?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:18","pubTimestamp":1765549108,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Friday, with the State Street Health Care Select Sector SPDR ETF  advancing by 0.6% and the iShares Biotechnology ETF  up 0.1%.Relay Therapeutics  shares were up more than 11% after the company said interim results from a study of zovegalisib plus fulvestrant to treat breast cancer patients showed \"robust activity.\"ImmunityBio  stock was up more than 4% after the company said the European Medicines Agency has recommended granting a conditional marketing authorization for anktiva in combination with BCG for the treatment of BGC-unresponsive non-muscle invasive bladder cancer.BioCryst Pharmaceuticals  shares were up more than 2% after the company said the US Food and Drug Administration approved Orladeyo oral pellets to help prevent hereditary angioedema attacks in children ages 2 to under 12.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4547","BK4585","BCRX","XBI","BK4581","RLAY","BK4139","IBB","BK4563","IBRX","XLV","LABU"],"gpt_icon":0},{"id":"2590878504","title":"Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday as Broadcom Results Deepen Fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2590878504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590878504?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:55","pubTimestamp":1765547734,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.5% lower in Friday's premarket activity as Broadcom's (AVGO) quar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f7a0f8aa044e4562b606d0f447f56531","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX","BETH",".IXIC","NX","TE","EQR","AVGO","EEM","IYK","FAS","RTH.AU","IVV","XLF","XRT","EETH","VIS","SPY","IYH","USO","XLI","IYW","SOXX","IPK","XLK","XLP","SPY.AU","IBB","IGV","IYJ","IGM","VHT","XSD","FAZ",".DJI","XLY","EXI","XLV","PMR","VDC","XLE","RTH","VHT.AU","BITO","IYE","UNG"],"gpt_icon":1},{"id":"2590506548","title":"BioCryst Pharmaceuticals Shares up 2.9% Premarket After FDA Nod of Rare Disease Drug for Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590506548?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:30","pubTimestamp":1765542606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2590250597","title":"FDA expands approval of BioCryst's rare disease drug for use in young children","url":"https://stock-news.laohu8.com/highlight/detail?id=2590250597","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590250597?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:05","pubTimestamp":1765541110,"startTime":"0","endTime":"0","summary":"FDA expands approval of BioCryst's rare disease drug for use in young childrenDec 12  - The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' BCRX.O drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":-0.0432},{"period":"1month","weight":-0.0634},{"period":"3month","weight":0.1044},{"period":"6month","weight":-0.1746},{"period":"1year","weight":-0.0756},{"period":"ytd","weight":-0.091}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.027354},{"month":2,"riseRate":0.516129,"avgChangeRate":-0.010813},{"month":3,"riseRate":0.354839,"avgChangeRate":0.014971},{"month":4,"riseRate":0.5625,"avgChangeRate":0.048894},{"month":5,"riseRate":0.5625,"avgChangeRate":0.062945},{"month":6,"riseRate":0.59375,"avgChangeRate":0.027194},{"month":7,"riseRate":0.5625,"avgChangeRate":0.113207},{"month":8,"riseRate":0.59375,"avgChangeRate":0.099672},{"month":9,"riseRate":0.34375,"avgChangeRate":-0.049493},{"month":10,"riseRate":0.5,"avgChangeRate":-0.046955},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.004698}],"exchange":"NASDAQ","name":"Biocryst Pharmaceuticals","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biocryst Pharmaceuticals,BCRX,Biocryst Pharmaceuticals股票,Biocryst Pharmaceuticals股票老虎,Biocryst Pharmaceuticals股票老虎国际,Biocryst Pharmaceuticals行情,Biocryst Pharmaceuticals股票行情,Biocryst Pharmaceuticals股价,Biocryst Pharmaceuticals股市,Biocryst Pharmaceuticals股票价格,Biocryst Pharmaceuticals股票交易,Biocryst Pharmaceuticals股票购买,Biocryst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}